679 studies on GLP-1R mechanism curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
Understanding the pharmacokinetic equivalence between daily and weekly dosing of semaglutide is crucial for optimizing drug development and patient care. If comparable steady-state exposure was achieved with daily adm…
If the EXER-MED trial demonstrates that combining exercise with tirzepatide leads to significantly better outcomes than medication alone, it could redefine the standard of care for obesity management. This research ha…
The successful completion of this Phase 1 study is a significant step forward in addressing pediatric obesity, a condition with limited pharmacological interventions. Tirzepatide, a dual GLP-1 and GIP receptor agonist…
The development of ALN-2232 represents a novel approach to treating obesity, potentially offering a new mechanism of action beyond existing therapies. If successful, this RNAi therapeutic could provide an important ne…
This comprehensive toxicological profile provides a crucial foundation for understanding the safety landscape of existing anti-diabetic drugs and informing the development of safer next-generation therapies. The ident…
This study highlights a crucial, previously under-recognized aspect of GLP-1RA therapy: its potential impact on male sexual health. The finding that GLP-1RAs may increase the risk of erectile dysfunction suggests that…
The findings suggest that GLP-1 Receptor Agonists could represent a novel, multi-faceted therapeutic strategy for stroke, offering both acute neuroprotection and long-term secondary prevention. Their ability to reduce…
This study highlights a critical safety signal, suggesting that GLP-1 receptor agonists may be associated with an increased risk of depressed mood and suicidal ideation in real-world settings. This finding underscores…
This study provides crucial evidence for clinicians and patients, highlighting the distinct advantages of metabolic and bariatric surgery in achieving more profound and sustained improvements in cardiometabolic risk p…
While specific results for the OASIS 3 trial are currently pending publication, this Phase 3 study was designed to demonstrate significant body weight reduction. Based on the established efficacy of semaglutide as a G…
Demonstrating the clinical comparability of drug products from different manufacturing processes is crucial for ensuring consistent drug quality, safety, and patient outcomes globally. This study's findings, once rele…
Understanding the precise impact of dosing variations on oral semaglutide pharmacokinetics is crucial for optimizing patient outcomes and adherence. This study provides robust data that reinforces the importance of cu…
The findings from this study are crucial because they will inform the safe and effective use of AD109 in a growing population of OSA patients who are also managing their weight or diabetes with GLP-1 medications. If A…
This pilot study is critically important because it addresses a significant clinical challenge: achieving healthy weight loss in older adults without compromising vital muscle and bone mass. If Tirzepatide can demonst…
This study provides compelling evidence that tirzepatide, a dual GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptor agonist, is significantly more effective than semaglutid…
This comprehensive review underscores the significant potential of GLP-1 receptor agonists as a novel therapeutic strategy for stroke prevention, particularly in patients with type 2 diabetes and obesity. Their abilit…
This study's findings are highly significant as they highlight the potential for semaglutide, a widely utilized medication, to improve fertility prospects within a challenging patient population. Obesity-related infer…
This research provides compelling evidence that Tirzepatide, a dual GIP/GLP-1 receptor agonist, may offer a novel therapeutic approach to improve outcomes for obese patients after TAVR. By significantly reducing subcl…
This study provides compelling evidence that combining GLP-1 receptor agonists with progestin therapy could be a highly effective and safe fertility-sparing treatment for EIN and early-stage endometrial cancer. The si…
This review highlights a paradigm shift in how dysglycemia might be managed in acute care settings. If GLP-1 RAs prove safe and effective in this population, they could offer a novel therapeutic strategy to improve ou…
Improved device design, particularly through automation, can significantly enhance patient safety and adherence for chronic conditions requiring frequent self-injection, such as type 2 diabetes and obesity. Reducing c…
The systematic review identified a consistent, albeit variable, reporting of hair loss among patients receiving GLP-1 receptor agonists. Across the analyzed studies, the incidence of alopecia ranged from approximately…
This systematic review provides compelling evidence that incretin-based therapies offer superior body composition benefits, promoting greater fat loss while better preserving crucial lean muscle mass, which is vital f…
This study provides robust real-world evidence suggesting a neuroprotective role for GLP-1 RAs, potentially offering a novel strategy for Parkinson's disease prevention or delaying its onset. These findings could pave…
This Phase 3 study, consistent with other trials, further validates semaglutide 2.4 mg as a highly effective pharmacological intervention for the treatment of obesity and overweight. The robust and sustained weight lo…
This pilot study is crucial because it addresses a significant unmet need for effective smoking cessation strategies in Type 2 diabetes patients, a group at high risk for cardiovascular complications. If semaglutide p…
The successful completion of this Phase 3 trial suggests semaglutide 2.4 mg could represent a significant advancement in the management of obesity and prediabetes. If the full results confirm substantial weight loss a…
If BGM0504 demonstrates comparable or superior efficacy to semaglutide with a favorable safety profile, it could represent a significant new therapeutic option for managing Type 2 Diabetes. This could provide a valuab…
If the results demonstrate a positive safety and efficacy profile, this study could pave the way for a novel adjunctive treatment strategy for a particularly challenging patient population. Adults with Type 1 Diabetes…
Establishing bioequivalence is crucial for pharmaceutical products, especially when manufacturing processes are altered, as it confirms that the drug's performance remains consistent. This finding means that patients …
The investigation of eloralintide, particularly in combination with tirzepatide, represents a significant step in developing next-generation treatments for obesity. If eloralintide demonstrates a favorable safety and …
Understanding the drug effect of Tirzepatide on musculoskeletal abnormalities is critical for optimizing obesity treatment strategies. This research could provide evidence for the necessity of combining GLP-1 therapie…
This study provides compelling evidence that PPARγ and GLP1 receptor agonists can directly improve brain metabolism and neuronal mitochondrial function, offering a novel therapeutic avenue for cognitive health. The us…
This research underscores the significant potential of microalgae as a sustainable and scalable bioreactor for producing novel therapeutic peptides with antidiabetic properties. The identification of potent hypoglycae…
This study provides crucial insights for plastic surgeons and patients, indicating that GLP-1 RA-induced weight loss may be associated with a slightly lower incidence of minor complications following body contouring s…
This comprehensive analysis provides crucial evidence for clinicians and patients in selecting the most effective GLP-1 receptor mono-agonist formulation for cardiometabolic improvement. The findings highlight the sup…
This study provides strong evidence that GLP-1 Receptor Agonists, exemplified by semaglutide, can directly improve cardiac function and clinical outcomes in patients with HFrEF, beyond their established metabolic bene…
This systematic review underscores the transformative potential of GLP-1 receptor agonists in the management of obesity and its associated health complications. The consistent and significant weight loss observed, cou…
This research highlights that tirzepatide offers substantial cardiovascular benefits, specifically in reducing blood pressure and improving heart function, independent of its known metabolic effects. The observed modu…
This research highlights a potentially significant benefit of GLP-1 receptor agonists in a high-risk population with advanced heart failure. While primarily known for managing diabetes and obesity, these findings sugg…
This "complex clinical encounter series" brings to the forefront a crucial, yet often underappreciated, aspect of GLP-1 RA therapy: its potential long-term impact on bone health. The key implication is that current cl…
This study holds significant promise for improving the lives of individuals with Type 1 Diabetes. If successful, the combination of a GLP-1 receptor agonist and an SGLT2 inhibitor with AID could offer a novel and high…
The identification of genetic predictors for GLP-1 response holds significant implications for personalized medicine in managing prediabetes, type 2 diabetes, and obesity. This research could lead to tailored therapeu…
Understanding the sex-based heterogeneity in drug response is crucial for optimizing personalized medicine approaches in CKMH. If significant differences are found, it could lead to sex-specific prescribing guidelines…
Understanding the nuanced differences in how GLP-1 receptor agonists and gastric bypass surgery affect body composition is crucial for optimizing treatment strategies for obesity. If GLP-1 RAs can achieve similar bene…
This research is highly significant as it targets a critical unmet need in Type 2 Diabetes management: patients who do not achieve adequate glycemic control even with potent GLP-1 or GLP-1/GIP receptor agonists. LY345…
This Phase 2a study is crucial because it targets a specific genetic subtype of MASLD that is often more aggressive and difficult to treat. ALN-PNP works by reducing the PNPLA3 protein, which is implicated in liver fa…